Bayer's growth-driving quintet? Better make it a trio, thanks to Stivarga and Xofigo stall
admin 3rd May 2018 Uncategorised 0Bayer blamed a strong euro for some obvious weak spots in its first-quarter numbers, but that explanation just doesn’t fly for its consumer health stall—or for the low turnout from cancer meds Xofigo and Stivarga. The company is hoping a new OTC chief can turn things around.
More: Bayer's growth-driving quintet? Better make it a trio, thanks to Stivarga and Xofigo stall
Source: fierce